This MHC class I reduction association with NLRC5 reduction relates to impaired CD8+ T-cell activation and poor patient prognosis.19 Upregulation of NLRC5 with promotion on MHC class I expression affiliates host immune system to combat cancer immune evasion, and contribute to cancer immunotherapy, including immune checkpoint inhibitors. Here, CD8A is linked to cancer.